- Conditions
- Advanced or Metastatic Solid Tumor, Advanced or Metastatic Gastric or Gastroesophageal Cancer, Myeloid or Lymphoid Neoplasms (MLN)
- Interventions
- Futibatinib
- Drug
- Lead sponsor
- Taiho Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 11
- States / cities
- Gilbert, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 169–192
of 2,243
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Colorectal Cancer Metastatic
- Interventions
- isunakinra
- Drug
- Lead sponsor
- Buzzard Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Newport Beach, California • Atlanta, Georgia
- Conditions
- Solid Tumor, Hodgkin's Lymphoma, NHL (Non-Hodgkin Lymphoma), Pancreatic Cancer, Breast Cancer, UC (Ureter and Urethera), Advanced Cancer, Metastatic Cancer
- Interventions
- INCB047986, Gemcitabine, nab-paclitaxel
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Nashville, Tennessee • Dallas, Texas
- Conditions
- Esophageal Neoplasms, Hepatocellular Carcinoma, Colorectal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Neoplasms
- Interventions
- Aroplatin (Liposomal NDDP, L-NDDP)
- Drug
- Lead sponsor
- Aronex Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Santa Monica, California
- Conditions
- Colorectal Cancer
- Interventions
- fluorouracil, gefitinib, irinotecan hydrochloride, leucovorin calcium
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Colorectal Neoplasms
- Interventions
- V941, Pembrolizumab
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 10
- States / cities
- Gilbert, Arizona • Duarte, California • San Francisco, California + 7 more
- Conditions
- Lung Cancer, Breast Cancer, Pancreatic Cancer, Head and Neck Cancer, Gastric Cancer
- Interventions
- 2-deoxy-D-glucose (2DG)
- Drug
- Lead sponsor
- Threshold Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 3
- States / cities
- Miami, Florida • Indianapolis, Indiana • San Antonio, Texas
- Conditions
- Colorectal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Recurrent Colorectal Carcinoma, Recurrent Pancreatic Carcinoma, Stage III Colorectal Cancer, Stage III Pancreatic Cancer, Stage IIIA Colorectal Cancer, Stage IIIB Colorectal Cancer, Stage IV Colorectal Cancer, Stage IV Pancreatic Cancer, Stage IVA Colorectal Cancer, Stage IVA Pancreatic Cancer, Stage IVB Colorectal Cancer, Stage IVB Pancreatic Cancer, Unresectable Pancreatic Carcinoma
- Interventions
- XL888, Pembrolizumab
- Drug · Biological
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia
- Conditions
- Gynecologic Cancer, Immunotherapy, Gut Microbiome
- Interventions
- Not listed
- Lead sponsor
- Viome
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Colorectal Cancer, HER2-expressing Non-small Cell Lung Cancer
- Interventions
- SBT6050, trastuzumab deruxtecan, tucatinib, trastuzumab, capecitabine
- Drug
- Lead sponsor
- Silverback Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Ovarian Neoplasms, Endometrial Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Gastroesophageal Junction Carcinoma, Uterine Cervical Neoplasms, Testicular Neoplasms
- Interventions
- SGN-ALPV
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 7
- States / cities
- Fresno, California • New Haven, Connecticut • Wellington, Florida + 4 more
- Conditions
- Advanced Cancer
- Interventions
- Avelumab, Utomilumab, PF-04518600, PD 0360324, CMP-001
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 409 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 57
- States / cities
- Encinitas, California • La Jolla, California • Los Angeles, California + 23 more
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Valemetostat, Atezolizumab, Bevacizumab
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Hepatocellular Carcinoma, Liver Cancer, HCC
- Interventions
- JX-594 recombinant vaccina GM-CSF, Best Supportive Care
- Biological · Other
- Lead sponsor
- Jennerex Biotherapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 11
- States / cities
- La Jolla, California • Orange, California • San Francisco, California + 8 more
- Conditions
- Pancreatic Cancer
- Interventions
- BPM31510 Nanosuspension Injection, Gemcitabine
- Drug
- Lead sponsor
- BPGbio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 9
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Gilroy, California + 6 more
- Conditions
- Hepatocellular Carcinoma, Cirrhosis, Liver
- Interventions
- Tremelimumab, Durvalumab
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Mucinous Adenocarcinoma of the Rectum, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Rectum, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer, Stage IIIA Rectal Cancer, Stage IIIB Rectal Cancer, Stage IIIC Rectal Cancer
- Interventions
- cytology specimen collection procedure, laboratory biomarker analysis
- Other
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Carcinoma, Hepatocellular, Head and Neck Neoplasms, Gastrointestinal Neoplasms
- Interventions
- BI 765049, ezabenlimab
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Los Angeles, California • Orange, California + 9 more
- Conditions
- Melanoma, Thyroid Cancer, Colorectal Cancer, Non-small Cell Lung Cancer, Cholangiocarcinoma, Histiocytosis, Hairy Cell Leukemia
- Interventions
- PLX8394
- Drug
- Lead sponsor
- Fore Biotherapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Salt Lake City, Utah • Spokane, Washington
- Conditions
- Esophageal Cancer
- Interventions
- cisplatin, Pemetrexed, radiation therapy
- Drug · Radiation
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Colorectal Cancer, Lung Cancer, Breast Cancer, Prostate Cancer
- Interventions
- Ad5 CEA Vaccine
- Biological
- Lead sponsor
- NantCell, Inc.
- Industry
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 2
- States / cities
- Durham, North Carolina • Spokane, Washington
- Conditions
- Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer, Non-Small Cell Lung Cancer Squamous, Non-Small Cell Lung Cancer Non-squamous, Colorectal Cancer (MSI-H), Gastric Cancer, Cervical Cancer, Basal Cell Carcinoma, Bladder Cancer, Merkel Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Cutaneous Squamous Cell Carcinoma, Pleural Mesothelioma, Esophageal Cancer, Endometrial Carcinoma, Solid Tumor, Solid Tumor, Adult, MSI-H Solid Malignant Tumor, Cancer With A High Tumor Mutational Burden, Epithelial Ovarian Carcinoma, Primary Peritoneal Cancer, Gastroesophageal Junction (GEJ) Cancer, Acral Melanoma, Mucosal Melanoma, Cutaneous Melanoma, DMMR Solid Malignant Tumor, Fallopian Tube Cancer, Ovarian Cancer, MSI-H Cancer, DMMR Cancer, Pancreas Adenocarcinoma (MSI-H), Skin Cancer, Viral Cancer, Cervical Cancers, Endometrial Cancer
- Interventions
- MDNA11, Pembrolizumab (KEYTRUDA®)
- Drug
- Lead sponsor
- Medicenna Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 7
- States / cities
- San Diego, California • San Francisco, California • Santa Monica, California + 4 more
- Conditions
- Adenocarcinoma, Pancreatic Neoplasms
- Interventions
- MLN8237, nab-Paclitaxel
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- HER2 Positive Gastric Cancer, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, EGFR Positive Solid Tumor, Advanced Solid Tumors, HER2-positive Breast Cancer, Hepatocellular Carcinoma, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Pancreatic Cancer, Melanoma
- Interventions
- FATE-NK100, Cetuximab, Trastuzumab
- Drug
- Lead sponsor
- Fate Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 4
- States / cities
- San Diego, California • Minneapolis, Minnesota • Columbus, Ohio + 1 more